drugset / Trial / NCT02150824

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

NCT02150824

Phase 2 Completed 103 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Assess the safety and tolerability of once daily oral doses of BI 187004 in patients with type 2 diabetes mellitus without oral antidiabetic treatment and in patients on a stable metformin background treatment over 28 days. Assess the effect on fasting plasma glucose after 28 days of treatment and to investigate the pharmacokinetics and pharmacodynamics of BI 187004.

Timeline

Start
2014-07
Primary completion
2015-07
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 187004 Small molecule Oral